Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...

Bioavailability: Influencing Factors

Bioavailability: Influencing Factors

Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Breast Cancer Hormone Receptor Status Determination from H&E-Stained Biopsy Images Using Pixel-Level Classifiers.

Cancers·2026

Same author

CHAMPION study protocol: children whose mothers are involved in the criminal justice system in Dorset & Hampshire, UK - developing health and social care outcome indicators.

BMJ open·2026

Same author

The impact of multiple long-term conditions on mortality, progression to kidney failure and health-related quality of life among people with chronic kidney disease: a multicentre cohort study (NURTuRE-CKD).

Annals of medicine·2026

Same author

LiRNA: An interactive atlas of human liver RNAseq databases.

JHEP reports : innovation in hepatology·2026

Same author

Flow-enhanced electrochemical aptamer sensor for nanomolar detection of NGAL in blood plasma for kidney injury diagnosis.

Biosensors & bioelectronics·2026

Same author

Chronic kidney disease in cirrhosis: a study of inpatients from a global perspective.

Gut·2026

Search research articles

Related Experiment Video

Updated: Jun 27, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study.

Oliver J Kennedy¹, Jonathan A Fallowfield², Robin Poole³

¹Primary Care & Population Sciences, Faculty of Medicine, University of Southampton, Southampton, SO17 1BJ, UK. ojk@doctors.org.uk.

BMC Public Health

|June 22, 2021

Summary

Drinking any type of coffee, including decaffeinated, instant, and ground, is associated with a reduced risk of chronic liver disease (CLD). This finding is significant for public health, as coffee may help prevent CLD onset or progression.

Keywords:

Chronic liver disease Cirrhosis Coffee Hepatocellular carcinoma

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Published on: January 27, 2023

Related Experiment Videos

Last Updated: Jun 27, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Published on: January 27, 2023

Area of Science:

Hepatology
Epidemiology
Nutritional Science

Background:

Chronic liver disease (CLD) is a significant global health concern, particularly in regions with limited treatment access.
Coffee consumption is inversely associated with CLD rates, but the impact of different coffee types remains unclear.

Purpose of the Study:

To investigate the association between various coffee types (decaffeinated, instant, ground) and chronic liver disease outcomes.
To analyze the protective effects of coffee consumption on CLD incidence, steatosis, hepatocellular carcinoma (HCC), and CLD-related mortality.

Main Methods:

Utilized UK Biobank data from 494,585 participants, linking coffee consumption to hospital, death, and cancer records.
Employed Cox regression to calculate hazard ratios (HR) for CLD and related outcomes based on coffee intake.
Differentiated analysis for overall coffee consumption and specific types: decaffeinated, instant, and ground coffee.

Main Results:

Coffee drinkers (n=384,818) showed significantly lower adjusted HRs for CLD (0.79), CLD or steatosis (0.80), and CLD death (0.51) compared to non-drinkers (n=109,767).
Similar protective associations were observed for all coffee types individually, including decaffeinated, instant, and ground coffee.
A trend towards reduced risk for hepatocellular carcinoma (HCC) was noted (HR 0.80), though not statistically significant (95% CI 0.54-1.19).

Conclusions:

All types of coffee consumption are associated with a reduced risk of chronic liver disease.
Coffee may serve as a potential dietary intervention to prevent the onset and progression of CLD.
Findings are significant given the rising global burden of CLD and the widespread availability of coffee.